Progress and challenges in Mesothelioma: from bench to bedside

Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi: 10.1016/j.rmed.2017.11.015)

153577.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Malignant Pleural Mesothelioma (MPM) is currently an incurable cancer with a typical survival of 1 year from the time of diagnosis. The recent genomic and transcriptomic characterization of MPM presents new opportunities and challenges for MPM researchers. Recent advances in clinical and laboratory diagnostics, and proposals for an updated, data-driven, staging system, also present new challenges for clinicians and hospital services involved in MPM care. The aim of this review is first to introduce the reader to the topic of MPM, a disease that is causally linked to prior, typically occupational, exposure to asbestos fibres. Secondly, we will discuss MPM from the clinical and laboratory perspectives, including reviews of current and evolving therapies and our present understanding of the molecular basis of the disease. Finally, we will attempt to identify critical knowledge gaps that currently prevent more effective treatment, including the challenges involved in early detection and chemoprophylaxis.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Murphy, Professor Daniel and Blyth, Professor Kevin
Authors: Blyth, K. G., and Murphy, D. J.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Respiratory Medicine
ISSN (Online):1532-3064
Published Online:26 November 2017
Copyright Holders:Copyright © 2017 Elsevier Ltd.
First Published:First published in Respiratory Medicine 134: 31-41
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
648131An examination of diagnostic and prognostic biomarkers in malignant pleural mesotheliomaKevin BlythOffice of the Chief Scientist (CSO)ETM/285SCHOOL OF MEDICINE, DENTISTRY & NURSING
3010320PRISM - Prediction of Resistance to chemotherapy using Somatic Copy Number Variation in MesotheliomaKevin BlythBritish Lung Foundation (BLF)MPG16-7Institute of Infection, Immunity & Inflammation
631971A versatile spatio-temporally inducible genetically engineered mouse model of mesotheliomaDaniel MurphyBritish Lung Foundation (BLF)APHD13-5RI CANCER SCIENCES
738121Pre-clinical evaluation of pan-ERBB inhibition to treat KRAS mutant NSCLCDaniel MurphyBritish Lung Foundation (BLF)CSOBLFRG16-2RI CANCER SCIENCES